ArticleOncoimmunology2020
Blood eosinophilic relative count is prognostic for breast cancer and associated with the presence of tumor at diagnosis and at time of relapse.
Article in Oncoimmunology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Eosinophils in solid cancers: sentinels, predictors, and therapeutic allies.Journal of experimental & clinical cancer research : CR · 2026Review
- Machine learning-based prediction of clinical outcomes in cervical cancer using routine hematological indices: development and web implementation.Frontiers in oncology · 2025Article
- Integrative analysis of homologous recombination repair patterns unveils prognostic signatures and immunotherapeutic insights in breast cancer.Journal of applied genetics · 2024Article
- The causal relationships of granulocytes and melanoma skin cancer: A univariable and multivariable Mendelian randomization study.Skin research and technology : official journal of International Society for Bioengineering and the Skin (ISBS) [and] International Society for Digital Imaging of Skin (ISDIS) [and] International Society for Skin Imaging (ISSI) · 2024Article
- Cost-effective prognostic evaluation of breast cancer: using a STAR nomogram model based on routine blood tests.Frontiers in endocrinology · 2024Article
- Article
- Type 1 and type 2 cytokine-mediated immune orchestration in the tumour microenvironment and their therapeutic potential.Exploration of targeted anti-tumor therapy · 2023Review
- Eosinophilia in cancer and its regulation by sex hormones.Trends in endocrinology and metabolism: TEM · 2023Review
- Excess of blood eosinophils prior to therapy correlates with worse prognosis in mesothelioma.Frontiers in immunology · 2023Article
- Eosinophils and melanoma: Implications for immunotherapy.Pigment cell & melanoma research · 2022Review
- Nutritional Regulation of Mammary Tumor Microenvironment.Frontiers in cell and developmental biology · 2022Review
- Review
- Review
- Immunity and Breast Cancer: Focus on Eosinophils.Biomedicines · 2021Review
- Review
- Peripheral blood eosinophilia may be a prognostic biomarker in non-small cell lung cancer patients treated with immunotherapy.Journal of thoracic disease · 2021Article
- Overexpression of MAL2 Correlates with Immune Infiltration and Poor Prognosis in Breast Cancer.Evidence-based complementary and alternative medicine : eCAM · 2021Article
- Article
- The Crosstalk Between Tumor Cells and the Immune Microenvironment in Breast Cancer: Implications for Immunotherapy.Frontiers in oncology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Cancer outcome is associated with circulating immune cells, including eosinophils. Here we analyze the relative eosinophil count (REC) in different breast cancer subtypes. Methods: Stage I-III breast cancer patients were included in the study and classified as REC-high vs low (cutoff 1.5%) or relative lymphocyte count (RLC)-high vs low (cutoff 17.5%). The co-primary endpoints were the breast cancer-specific survival (BCSS) or the time to treatment failure (TTF) in the REC groups. Results: Overall 930 patients were included in the study. We observed a benefit for REC-high vs REC-low in TTF (HR 0.610, 95% CI 0.458-0.812), and in BCSS (HR 0.632, 95% CI 0.433-0.923). Similarly, we observed a better TTF (HR 0.421, 95% CI 0.262-0.677) and BCSS (HR 0.350, 95% CI 0.200-0.614) in RLC-high vs low. A lower relapse rate was observed in the REC-high Conclusions: REC could be a new promising, affordable and accessible predictive and prognostic biomarker in all breast cancer subtypes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.